98%
921
2 minutes
20
Background And Aims: Over-the-counter codeine products were up-scheduled to prescription only in Australia from February 2018. This trend study aimed to identify changes in codeine supply before and after the February 2018 implementation.
Design, Setting And Cases: Time-series regression analysis of monthly medicine supplies in Australia from 2014 to 2018. The February 2018 up-scheduling was pre-specified as the intervention; outlier analysis was used to detect automatically sudden unexpected changes before February 2018.
Measurements: Per-capita supplies based on national data for pharmaceutical wholesales and population exposure. Weight of supplies in milligrams for low-dose codeine (≤ 15 mg per tablet or ≤ 1.92 mg per ml, originally sold over the counter but up-scheduled after February 2018), high-dose combination codeine (30 mg per tablet, prescription only throughout the study period) and all codeine.
Findings: Several level shifts in supply occurred during the 5 years, led by one of -4.4% [95% confidence interval (CI) = -6.6 to -2.1%] in high-dose codeine in 2015, followed by shifts in low-dose codeine of -40.0% (CI = -46.9 to -32.3%) and -82.2% (CI = -84.3 to -79.9%), respectively, before and after February 2018. High-dose codeine supply increased by 4.4% (CI = 1.8-7.1%) immediately after up-scheduling. Also detected were transient increases and decreases in 2016 and 2017. Compared with pre-2015 levels, the February 2018 up-scheduling was associated with reductions of 45.7% (CI = 43.2-48.0%) and 89.3% (CI = 87.9-90.6%), respectively, in all and low-dose codeine supply but no change in high-dose codeine supply. The level shifts and transient changes were located around various regulatory activities, including public announcements and expert advisory meetings on up-scheduling.
Conclusion: Up-scheduling of over-the-counter codeine products in Australia in 2018 appears to have been associated with a near halving of Australia's national codeine supply. The transition occurred in multiple forms and phases.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/add.15566 | DOI Listing |
Anal Chem
May 2025
Department of Chemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon 999077, Hong Kong.
Current drug detection methods, such as blood and urine analysis, are often invasive and raise ethical and privacy concerns. This study demonstrates that breathing through typical polypropylene-based meltblown cloth face masks is an efficient and user-friendly method for collecting drugs from exhaled breath for analysis. By using codeine, ephedrine, guaifenesin, and chlorpheniramine found in cough syrup as model compounds, we found that these face masks achieved a collection efficiency exceeding 92% for the tested drugs.
View Article and Find Full Text PDFDrug Alcohol Rev
May 2025
Department of Community Health and Epidemiology, Dalhousie University, Halifax, Canada.
Introduction: To describe opioid prescribing patterns for opioid-naive patients who filled prescriptions after surgical or emergency care.
Methods: We conducted a population-based, cross-sectional study of opioid-naive adults who filled opioid prescriptions within 14 days of receiving surgical or emergency care in Nova Scotia, Canada. Using linked administrative databases, we estimated the prevalence of opioid prescriptions with >7 days' supply, ≥90 morphine milligram equivalents (MME)/day or long-acting opioids.
Pharmacoepidemiol Drug Saf
December 2024
Department of Behavioral Science, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Brain Behav Immun
February 2025
Neuroscience Graduate Program, The Ohio State University, Columbus, OH, USA; Department of Psychology, The Ohio State University, Columbus, OH, USA; Department of Neuroscience, The Ohio State University, Columbus, OH, USA; Institute for Behavioral Medicine Research, The Ohio State University, Columb
7 % of pregnant people use opioids. Opioid use during pregnancy can negatively impact maternal and offspring health. Medications for opioid use disorder (MOUD), commonly buprenorphine, are the recommended treatment for opioid use disorder during pregnancy to prevent cycles of withdrawal and relapse.
View Article and Find Full Text PDF